Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED 精優藥業控股有限公司*

(Incorporated in Bermuda with limited liability)
(Stock Code: 00858)

FURTHER DELAY IN DESPATCH OF CIRCULAR IN RELATION TO MAJOR AND CONNECTED TRANSACTION CONCERNING THE DISPOSAL OF 51% SHAREHOLDING INTEREST IN SMART ASCENT LIMITED

Reference is made to the announcement of Extrawell Pharmaceutical Holdings Limited dated 30 April 2014 (the "**Delay Announcement**") and the announcements dated 14 May 2014 and 30 May 2014 regarding the delay in despatch of circular in relation to major and connected transaction concerning the disposal of 51% shareholding interest in Smart Ascent Limited. Capitalized terms used herein shall have the same meanings as defined in the Delay Announcement unless the context requires otherwise.

The Board wishes to announce that as additional time is required to finalize certain information to be included in the Circular, it is expected that the despatch of the Circular will be further postponed to a date on or before 25 June 2014.

By order of the Board

Extrawell Pharmaceutical Holdings Limited

Xie Yi

Chairman

Hong Kong, 12 June 2014

As at the date of this announcement, the Board comprises executive directors as Dr. Xie Yi, Dr. Lou Yi, Mr. Cheng Yong, Ms. Wong Sau Kuen and Mr. Liu Kwok Wah and independent non-executive directors as Mr. Fang Lin Hu, Mr. Xue Jing Lun and Ms. Jin Song.

* For identification purpose only